|
FDA Rolls Out Long-Awaited Opioid REMS
Manufacturers of extended-release and long-acting (ER/LA) opioid pain relievers will need to have educational programs available for prescribers by March of next year, according to a new classwide risk evaluation and mitigation strategy (REMS) that has been in the works for years.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives